PSMA antibody, humanized PSMA.CAR10.3, or Cetuximab increases prostate cancer localization of NF-κB p50-deficient immature myeloid cells (p50-IMC) and phagocytosis by their macrophage progeny
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-024-03939-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Mohammad A Alzubi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Oncology, Department of Oncology, Johns Hopkins University, CRB I, Rm. 253, 1650 Orleans St., Baltimore, MD, 21231, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Phagocytosis, Cetuximab, Macrophages. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, Department of Defense Prostate Cancer Research Program.
Abstract (Originalsprache)
Adoptive transfer of immature myeloid cells lacking the repressive NF-κB p50 subunit (p50-IMC) slows the growth of syngeneic murine prostate cancer and other tumors. Directing p50-IMC to tumors using Fc receptor-bound antibodies (Abs) or surface chimeric antigen receptors (CARs) may increase tumor localization and subsequent phagocytosis of cancer cells by their mature myeloid progeny, potentiating anti-tumor T cell activation. PSMA and EGFR are found on aggressive human prostate cancers, and p50-IMC express receptors that bind the antibody Fc domain. p50-IMC combined with PSMA Ab, EGFR Ab (Cetuximab), or fully humanized PSMA.CAR10.3 manifest increased localization to Myc-CaP murine prostate cancer tumors expressing PSMA or EGFR. Tumor localization is further increased when myelo-depleting 5-fluorouracil precedes p50-IMC administration. Additionally, we find that PSMA Ab, EGFR Ab, or PSMA.CAR10.3 increase in vitro phagocytosis of Myc-CaP cells expressing PSMA or EGFR by p50-IMC-derived macrophages, including in M2-promoting IL-4, which is a component of the immune-suppressive tumor microenvironment. Lack of tolerance of human PSMA or EGFR by immune-competent mice and lack of expression of human PSMA protein in the prostate of AR 2 -Probasin-hPSMA transgenic mice precluded our ability to determine whether human-specific PSMA or EGFR antibody or PSMA.CAR10.3 increases anti-tumor efficacy of murine p50-IMC. Nevertheless, this study indicates the potential clinical utility of adding a tumor-directing antibody or CAR, including the novel, fully humanized PSMA.CAR10.3, to proinflammatory p50-IMC to optimize the activation of anti-tumor immunity in prostate cancer and other malignancies, and understanding PSMA toxicity in normal but not malignant prostate epithelium may reveal a novel therapeutic opportunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Oncology, Department of Oncology, Johns Hopkins University, CRB I, Rm. 253, 1650 Orleans St., Baltimore, MD, 21231, USA.
- Division of Pediatric Oncology, Department of Oncology, Johns Hopkins University, CRB I, Rm. 253, 1650 Orleans St., Baltimore, MD, 21231, USA. afriedm2@jhmi.edu.
ORCID-Profile: Mohammad A Alzubi, Theresa Barberi, Alan D Friedman
Förderung
- NCI NIH HHS
- NIH HHS
- Department of Defense Prostate Cancer Research Program
- National Institutes of Health
Zitieren
APA
Alzubi, M. A., Barberi, T., & Friedman, A. D. (2025). PSMA antibody, humanized PSMA.CAR10.3, or Cetuximab increases prostate cancer localization of NF-κB p50-deficient immature myeloid cells (p50-IMC) and phagocytosis by their macrophage progeny. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03939-4
Vancouver
Alzubi MA, Barberi T, Friedman AD. PSMA antibody, humanized PSMA.CAR10.3, or Cetuximab increases prostate cancer localization of NF-κB p50-deficient immature myeloid cells (p50-IMC) and phagocytosis by their macrophage progeny. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-024-03939-4
BibTeX
@article{Alzubi2025,
author = {Alzubi, Mohammad A and Barberi, Theresa and Friedman, Alan D},
title = {PSMA antibody, humanized PSMA.CAR10.3, or Cetuximab increases prostate cancer localization of NF-κB p50-deficient immature myeloid cells (p50-IMC) and phagocytosis by their macrophage progeny},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-024-03939-4}
}
EUVIMED